It would therefore seem appropriate that patients with confirmed pathogenic DNM1L variants follow a cardiac surveillance programme, as is in place for other forms of mitochondrial disease, with a view to appropriate pre-emptive treatment. The gene discussed is DNM1L; the disease is inborn mitochondrial metabolism disorder.